All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for UCB, INC. · Biopharmaceutical company

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

Georgia

Official filing document

Government bodies contacted 5

Centers For Medicare and Medicaid Services (CMS)
Executive Office of the President (EOP)
HOUSE OF REPRESENTATIVES
Office of Management & Budget (OMB)
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 5

HR 993
Emerging Innovative Border Technologies Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 591
Defending American Jobs and Investment Act
HR 2423
Unfair Tax Prevention Act
S 864
HELP Copays Act

Lobbying activity 4

Taxation/Internal Revenue Code

Monitor implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes. Monitor OECD negotiations related to Pillar II global minimum tax. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations.

Health Issues

Issues related to medication step therapy. S.864, HELP Copays Act, as it relates to out-of-pocket costs for prescription drugs. Issues related to pharmacy benefit management reforms.

Trade (domestic/foreign)

Issues related to tariffs.

Medicare/Medicaid

Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Issues related to access to home infusion, including H.R. 993, Joe Fiandra Access to Home infusion Act of 2025. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.